Last updated: November 3, 2026

Darvocet-N 50 was a fixed-dose analgesic containing propoxyphene napsylate 50 mg and acetaminophen 650 mg. Its U.S. commercial market ended in November 2010 after the FDA concluded that propoxyphene created serious cardiac risks, including potentially fatal arrhythmias. The product had no meaningful remaining U.S. patent protection at withdrawal, and its financial decline resulted from generic erosion, opioid-safety scrutiny, declining clinical use, and regulatory removal rather than patent expiry alone. Product-specific revenue was not publicly reported by Xanodyne Pharmaceuticals.

What was Darvocet-N 50 and who marketed it?

Darvocet-N 50 combined the opioid propoxyphene napsylate with acetaminophen. The “N” designation identified the napsylate salt. The 50-mg product contained half the propoxyphene dose of Darvocet-N 100, while both products contained 650 mg of acetaminophen per tablet.

Attribute	Darvocet-N 50
Active ingredients	Propoxyphene napsylate 50 mg; acetaminophen 650 mg
Dosage form	Immediate-release tablet
Therapeutic category	Prescription opioid analgesic
U.S. sponsor at withdrawal	Xanodyne Pharmaceuticals
U.S. regulatory status	Withdrawn from the market in 2010
FDA safety issue	Cardiac conduction abnormalities and overdose risk
Patent position at withdrawal	No material remaining exclusivity barrier identified
Current U.S. commercial status	Not marketed

The product originated in the older propoxyphene franchise associated with Eli Lilly’s Darvon and Darvocet brands. Xanodyne held the U.S. commercial rights when the FDA requested withdrawal in 2010.

When did Darvocet-N 50 lose exclusivity?

Darvocet-N 50 was a mature product long before its withdrawal. Its active ingredient had been used in the United States since the 1950s, and generic propoxyphene products competed with the branded product for many years.

The key commercial milestones were:

Period	Market event	Financial effect
1950s onward	Propoxyphene products established in the U.S. analgesic market	Created a long-lived branded franchise
1980s-1990s	Generic propoxyphene and acetaminophen products expanded	Reduced branded pricing power
2000s	Safety warnings, abuse concerns, and opioid alternatives increased	Lowered prescribing and brand value
2009	FDA review identified dose-related cardiac risk	Increased regulatory and liability exposure
November 2010	FDA requested withdrawal of propoxyphene products	Eliminated U.S. product revenue
After 2010	U.S. Darvocet and generic propoxyphene products were removed	No continuing U.S. sales base

Darvocet-N 50 was therefore exposed to conventional generic competition before the FDA action. Its commercial exclusivity had effectively ended through patent expiration and market substitution well before regulatory withdrawal.

What was the FDA regulatory status of Darvocet-N 50?

The FDA announced on November 19, 2010, that Xanodyne had agreed to voluntarily withdraw Darvon, Darvocet, and related propoxyphene products from the U.S. market. The agency cited new evidence that propoxyphene could alter cardiac electrical activity and cause serious or fatal arrhythmias, even at therapeutic doses [1].

The FDA had previously required stronger warnings and a boxed warning concerning overdose, respiratory depression, and suicide risk. The 2010 action followed an FDA-requested study showing dose-dependent changes in the QT interval, a marker of cardiac electrical instability [1].

The regulatory outcome was more severe than a labeling restriction:

Xanodyne withdrew the branded products.
Generic manufacturers discontinued propoxyphene products.
Pharmacies and prescribers were instructed to stop dispensing and prescribing the medicine.
The FDA advised patients to transition to alternative pain treatments under medical supervision.

The product did not lose market share gradually after 2010. It lost its U.S. market entirely.

What was the Orange Book status of Darvocet-N 50?

Darvocet-N 50 did not have a commercially meaningful Orange Book patent position when it was withdrawn. The principal business constraint was regulatory removal, not an unexpired formulation or method-of-use patent.

The relevant Orange Book analysis is:

Issue	Assessment
Listed drug	Darvocet-N 50 was an approved prescription product before withdrawal
Active patent exclusivity	No material remaining protection identified at the time of withdrawal
Paragraph IV exposure	Historically relevant to generic entry, but not a current commercial issue
Formulation patent	No publicly significant later-generation formulation estate
Method-of-use patent	No commercially important patent blocking withdrawal
Current Orange Book value	No practical market-exclusion value after discontinuation

The product’s fixed-dose combination was not protected by a durable modern delivery system, abuse-deterrent formulation, extended-release technology, or device platform. Its intellectual-property position was consistent with an older small-molecule analgesic.

How many patents covered Darvocet-N 50?

The product was not supported by a modern, layered patent estate. The original compound and combination-product rights were old, and generic competition had already developed before withdrawal.

The principal categories of potentially relevant rights were:

Historical composition or salt patents covering propoxyphene or its napsylate form.
Combination-product claims covering propoxyphene with acetaminophen.
Manufacturing or formulation claims associated with tablet production.
Regulatory exclusivity associated with the original approval.

None created a current barrier to generic entry by 2010. The absence of a defensible late-life patent strategy limited Xanodyne’s ability to preserve value through reformulation or lifecycle management.

No credible evidence indicates that Darvocet-N 50 had an unexpired patent comparable to the formulation estates supporting newer branded analgesics.

What generic entry risks affected Darvocet-N 50?

Generic erosion was a structural risk throughout the product’s commercial life. Propoxyphene-acetaminophen tablets were available from multiple manufacturers before the FDA withdrawal. Because the active ingredients were conventional small molecules delivered in an immediate-release tablet, substitution risk was high.

The product lacked several features that can delay generic competition:

No biologic complexity.
No injectable or device-based delivery system.
No extended-release technology with meaningful remaining patent life.
No proprietary abuse-deterrent platform.
No difficult-to-reproduce manufacturing process.
No clinically differentiated formulation.
No durable method-of-use exclusivity.

Paragraph IV litigation may have been relevant during the earlier generic approval cycle, but it had no material role in the final market outcome. By 2010, generic competition was established, and the FDA withdrawal eliminated both branded and generic U.S. sales.

What patent litigation and liability litigation affected the product?

The major late-stage legal exposure involved product liability and regulatory risk rather than an active patent dispute.

Following the withdrawal, federal litigation involving Darvocet, Darvon, and propoxyphene products was centralized in multidistrict proceedings. The litigation alleged injuries associated with cardiac events, overdose, dependence, and other adverse effects. The existence of these proceedings increased the expected cost of maintaining the franchise and reduced the economic value of any remaining commercial rights [2].

The legal risk profile included:

Risk category	Effect on commercial value
Patent litigation	Low by the end of the product’s life
Product liability	High after cardiac-risk findings
Regulatory enforcement	High because continued distribution was no longer viable
Labeling exposure	High due to prior safety warnings
Medical-monitoring and injury claims	Increased post-withdrawal liabilities
Settlement value	Dependent on claimant volume, causation, insurance, and corporate resources

The withdrawal did not eliminate potential liability for prior exposure. It stopped new U.S. sales while leaving historical claims and litigation costs.

What was the financial trajectory of Darvocet-N 50?

Xanodyne was a privately held company, and public filings do not provide a reliable standalone revenue series for Darvocet-N 50. Publicly available data therefore support a directional financial analysis rather than a precise product-level revenue forecast.

Revenue trajectory

Financial phase	Commercial condition	Revenue direction
Mature branded period	Established prescribing base and broad physician familiarity	Stable to declining
Generic erosion period	Lower-priced substitutes and reduced branded share	Declining net sales and margin
Safety-warning period	Reduced prescribing and increased monitoring	Accelerated decline
Pre-withdrawal period	FDA cardiac-risk review and physician substitution	Rapid deterioration
Post-November 2010	U.S. withdrawal	Zero U.S. product revenue

Darvocet-N 50’s economics were likely based on volume, brand recognition, and an established prescribing base rather than premium pricing. Those economics deteriorated as generic alternatives became available and as prescribers shifted to other analgesics.

The product’s final financial value was likely concentrated in:

Remaining inventory.
Distribution rights before withdrawal.
Historical brand recognition.
Potential international rights, subject to local regulatory status.
Litigation and liability management.

The FDA action converted the franchise from a declining commercial asset into a liability-management problem.

How did Darvocet-N 50 compare with competing pain medicines?

Darvocet-N 50 competed with low-dose opioid combinations and nonopioid analgesics. Its clinical position weakened because the product offered modest analgesic utility while carrying opioid, acetaminophen, and cardiac risks.

Product category	Competitive position versus Darvocet-N 50
Hydrocodone-acetaminophen	Greater analgesic potency and broader adoption, but higher controlled-substance scrutiny
Codeine-acetaminophen	Similar combination concept with variable efficacy and safety concerns
Tramadol	Positioned as an alternative for moderate pain before later opioid-risk concerns
NSAIDs	Nonopioid alternatives with different gastrointestinal, renal, and cardiovascular risks
Acetaminophen alone	Lower abuse potential but weaker efficacy for some patients
Extended-release opioids	Higher potency and different chronic-pain positioning

Darvocet-N 50 had no clear long-term differentiation against these alternatives. Its low dose did not compensate for the cardiac-risk findings, and its acetaminophen component limited the ability to increase dosing safely.

What licensing deals affected Darvocet-N 50?

The relevant commercial transaction was the transfer of U.S. Darvon and Darvocet rights to Xanodyne Pharmaceuticals from the prior brand owner. Public information does not establish a later licensing transaction that preserved the value of Darvocet-N 50 after the FDA withdrawal.

No publicly documented deal created a reformulated, abuse-deterrent, extended-release, or international growth platform for the product after 2010. The absence of a successor product limited opportunities to monetize the brand through lifecycle management.

What generic launch scenarios existed for Darvocet-N 50?

Before withdrawal, generic substitution was the dominant launch scenario. A generic manufacturer could compete through an abbreviated new drug application because the product was a conventional immediate-release combination tablet with a long history of use.

The commercial scenarios were:

Generic entry with rapid pharmacy substitution.
Continued low-price branded sales in selected channels.
Further decline after opioid warnings.
Complete market exit following FDA withdrawal.

The fourth scenario occurred. The regulatory action prevented a conventional post-patent competition cycle from continuing.

Did Darvocet-N 50 create biosimilar risk?

No. Biosimilar risk does not apply because Darvocet-N 50 was a chemically synthesized small-molecule tablet, not a biologic. The relevant competitive threats were generic substitution, therapeutic substitution, safety restrictions, and regulatory withdrawal.

What is the current commercial outlook for Darvocet-N 50?

Darvocet-N 50 has no active U.S. commercial outlook. Reintroduction would require a new regulatory and clinical strategy addressing the cardiac-risk findings, the availability of safer alternatives, controlled-substance requirements, and historical liability. A simple reapproval or relaunch would not restore the former franchise economics.

The product also lacks a defensible patent moat. Any commercial revival would face immediate substitution risk unless supported by a materially differentiated formulation, delivery system, or new clinical use. Such a strategy would require substantial development investment without an obvious regulatory or market rationale.

Key Takeaways

Darvocet-N 50 contained propoxyphene napsylate 50 mg and acetaminophen 650 mg.
Xanodyne Pharmaceuticals marketed the product in the United States at the time of withdrawal.
The FDA removed it from the U.S. market in November 2010 because of potentially fatal cardiac risks.
Its patent estate was old and did not provide meaningful protection at the end of its commercial life.
Generic competition and therapeutic substitution had already weakened the brand.
Product-specific revenue was not publicly disclosed by Xanodyne.
The financial trajectory ended with the loss of U.S. sales and increased product-liability exposure.
Biosimilar risk was irrelevant; generic and regulatory risks determined the product’s outcome.
No current U.S. commercial market or credible relaunch pathway exists.

FAQs About Darvocet-N 50

Is Darvocet-N 50 still available in the United States?

No. U.S. Darvocet and related propoxyphene products were withdrawn in 2010 following FDA safety findings.

Why was Darvocet-N 50 discontinued?

The FDA concluded that propoxyphene could cause serious cardiac electrical abnormalities and fatal arrhythmias, including at therapeutic exposure levels.

Did Darvocet-N 50 have an abuse-deterrent formulation?

No. Darvocet-N 50 was an immediate-release tablet without a modern abuse-deterrent delivery platform.

Was Darvocet-N 50 more valuable than Darvocet-N 100?

There is no public product-level financial evidence supporting that conclusion. The 50-mg product had lower propoxyphene strength, but both products were exposed to generic competition and the same fundamental safety concerns.

Could a generic company relaunch Darvocet-N 50?

A U.S. relaunch would require FDA authorization and would face substantial regulatory, clinical, liability, and market-access obstacles. Patent expiration would not be the primary barrier.

References

U.S. Food and Drug Administration. (2010, November 19). FDA drug safety communication: FDA recommends against the continued use of propoxyphene. https://www.fda.gov
Judicial Panel on Multidistrict Litigation. (2011). In re: Darvocet, Darvon and propoxyphene products liability litigation, MDL No. 2226. United States District Court records.
U.S. Food and Drug Administration. (2009). Darvocet-N 50 prescribing information. Drugs@FDA.
U.S. Food and Drug Administration. (2010). FDA announces voluntary withdrawal of propoxyphene products. https://www.fda.gov

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
DailyMed Link:	DARVOCET-N 50 at DailyMed

Sponsor	Phase
University of Rochester	Phase 4
Endo Pharmaceuticals	Phase 4

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xanodyne Pharm	DARVOCET-N 50	acetaminophen; propoxyphene napsylate	TABLET;ORAL	017122-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DARVOCET-N 50 Drug Patent Profile

Which patents cover Darvocet-n 50, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for DARVOCET-N 50

Recent Clinical Trials for DARVOCET-N 50

US Patents and Regulatory Information for DARVOCET-N 50

Darvocet-N 50 Market Dynamics and Financial Trajectory